Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
TLPH
Talphera, Inc.
The company emphasizes drug delivery platform concepts through lyophilized nafamostat formulations and IV/compounded administration approaches.
|
$26.88M |
$1.31
-0.38%
|
|
RLYB
Rallybio Corporation
Core focus on rare diseases with lead and preclinical assets addressing complement dysregulation and iron overload.
|
$26.87M |
$0.65
-0.32%
|
|
DSY
Big Tree Cloud Holdings Limited
Provides OEM/ODM manufacturing services, i.e., contract manufacturing for others.
|
$26.83M |
$0.47
+2.85%
|
|
NERV
Minerva Neurosciences, Inc.
Minerva focuses on neuropsychiatric drug development (roluperidone for schizophrenia negative symptoms).
|
$26.44M |
$3.84
+1.86%
|
|
STCB
Starco Brands, Inc.
Vertical integration via acquisition of The Starco Group provides contract manufacturing capabilities.
|
$25.88M |
$0.04
|
|
CLGN
CollPlant Biotechnologies Ltd.
rhCollagen is a recombinant protein, and CollPlant's core product is plant-derived recombinant human collagen used in implants, fillers, and bioinks.
|
$25.54M |
$2.13
-4.69%
|
|
LIMN
Liminatus Pharma, Inc. Class A Common Stock
Directly aligned with LIMN's focus on cancer therapies (anti-CD47 antibody) within the biotech-oncology space.
|
$25.39M |
$0.99
+11.85%
|
|
QTTB
Q32 Bio Inc.
Bempikibart is a fully human monoclonal antibody targeting IL-7Rα, a core monoclonal antibody therapeutic category.
|
$25.13M |
$2.08
+2.46%
|
|
BOLD
Boundless Bio, Inc.
The company is a biotechnology firm focused on oncology, developing ecDNA-directed cancer therapies, which places it in Biotech - Oncology.
|
$24.85M |
$1.11
+0.45%
|
|
DARE
Daré Bioscience, Inc.
Drug Delivery Platforms: Daré's core IDDS platform is used to deliver hormones and contraceptive agents (e.g., DARE-LARC1) and supports multiple pipeline programs, making this a primary product/technology category.
|
$24.40M |
$1.85
+4.52%
|
|
XCUR
Exicure, Inc.
GPCR USA's lead asset GPC-100.00 is an oncology biotech product in development, representing the core biotech asset.
|
$24.39M |
$3.83
+0.26%
|
|
IBIO
iBio, Inc.
The company markets and utilizes an Antibody Discovery Platform (epitope-steering AI, StableHu, EngageTx, ShieldTx) to identify and optimize antibody candidates.
|
$23.59M |
$1.21
+2.99%
|
|
CVM
CEL-SCI Corporation
Direct product category for CEL-SCI's lead immunotherapy for cancer (Multikine) under oncology biotech.
|
$22.79M |
$7.73
+15.20%
|
|
AKTX
Akari Therapeutics, Plc
Core product category: antibody-drug conjugates (ADC) platform and lead AKTX-101 using PH1 payload targeting Trop2.
|
$22.08M |
$0.46
+3.45%
|
|
NAII
Natural Alternatives International, Inc.
Direct contract manufacturing services for private-label vitamins, minerals, herbal and other health care products.
|
$21.99M |
$3.64
|
|
GDTC
CytoMed Therapeutics Limited
Core business platform focuses on cell-based immunotherapies (gamma delta T cells, NK cells), aligning with Biotech - Cell Therapy.
|
$21.93M |
$1.88
-1.05%
|
|
ITRM
Iterum Therapeutics plc
ORLYNVAH is an oral small molecule antibiotic (sulopenem) that the company is launching commercially.
|
$20.95M |
$0.47
+7.51%
|
|
AYTU
Aytu BioPharma, Inc.
AYTU's core ADHD portfolio comprises oral small-molecule therapeutics (Adzenys XR-ODT, Cotempla XR-ODT) and Karbinal ER, fitting the 'Oral Small Molecule Therapeutics' category.
|
$20.82M |
$2.13
+0.71%
|
|
PALI
Palisade Bio, Inc.
PALI-2108 is an orally administered small molecule therapeutic, matching the Oral Small Molecule Therapeutics tag.
|
$20.34M |
$2.22
+3.26%
|
|
ENLV
Enlivex Therapeutics Ltd.
Allocetra is Enlivex's lead cell therapy platform, directly produced and administered as a therapeutic cell product.
|
$19.79M |
$0.91
-7.55%
|
|
LEXX
Lexaria Bioscience Corp.
Lexaria's DehydraTECH is a proprietary drug delivery platform that enhances API absorption and enables oral formulations.
|
$19.67M |
$1.12
+3.70%
|
|
SYBX
Synlogic, Inc.
PKU is a rare metabolic disease and Synlogic's lead programs target rare diseases via a synthetic biology platform.
|
$19.30M |
$1.69
+1.20%
|
|
LIXT
Lixte Biotechnology Holdings, Inc.
LB-100 is Lixte's lead oncology drug candidate (PP2A inhibitor) being developed for cancer therapy, constituting the primary product/offerable asset.
|
$19.20M |
$4.24
+3.67%
|
|
CVKD
Cadrenal Therapeutics, Inc. Common Stock
Cadrenal's tecarfarin is described as a novel oral small-molecule therapeutic, directly aligning with the 'Oral Small Molecule Therapeutics' tag.
|
$19.20M |
$9.69
-2.32%
|
|
COSM
Cosmos Health Inc.
Owns/operates in-house EU GMP manufacturing via Cana Laboratories Holdings Cyprus Ltd. and Cana S.A., enabling contract manufacturing revenue.
|
$19.14M |
$0.63
+0.70%
|
|
INTS
Intensity Therapeutics, Inc.
Company develops oncology-focused therapeutics (INT230-6.00) and operates in Biotech - Oncology.
|
$18.65M |
$0.40
+1.34%
|
|
ALLR
Allarity Therapeutics, Inc.
Allarity is a clinical-stage biotech focused on oncology therapies (stenoparib) and cancer drug development.
|
$18.27M |
$1.26
+7.20%
|
|
PYPD
PolyPid Ltd.
D-PLEX100 leverages PolyPid's PLEX drug-delivery platform to provide localized, prolonged antibiotic release at the surgical site.
|
$18.23M |
$3.77
+2.45%
|
|
TRAW
Traws Pharma, Inc.
Company is developing Antiviral Small-Molecule Therapeutics (ratutrelvir) for COVID-19 as a core antiviral program.
|
$18.08M |
$2.57
-2.28%
|
|
LSTA
Lisata Therapeutics, Inc.
Certepetide is a proprietary peptide therapeutic, fitting Peptide Therapeutics.
|
$17.95M |
$2.06
-0.24%
|
|
ATHA
Athira Pharma, Inc.
ATH-1105 is described as an orally available, brain-penetrant small molecule developed for ALS, fitting the 'Oral Small Molecule Therapeutics' tag.
|
$17.83M |
$4.77
+6.24%
|
|
LPCN
Lipocine Inc.
Lipocine leverages the proprietary Lipral drug delivery platform, a core asset that enables oral delivery of challenging molecules and underpins its product candidates.
|
$17.77M |
$3.33
+1.83%
|
|
EVOK
Evoke Pharma, Inc.
Gimoti relies on a nasal drug-delivery platform/technology, making Drug Delivery Platforms a core investable theme for Evoke's product strategy.
|
$16.89M |
$10.86
+0.51%
|
|
APLM
Apollomics, Inc.
The company is a biotechnology oncology-focused firm actively developing cancer therapies (vebreltinib and apolecylin) with multiple clinical programs.
|
$16.76M |
$17.14
+6.20%
|
|
PULM
Pulmatrix, Inc.
Pulmatrix's core offering is the iSPERSE dry powder drug delivery platform, a direct product category.
|
$16.40M |
$4.54
+5.21%
|
|
HOTH
Hoth Therapeutics, Inc.
HT-001 (oncology supportive care) and HT-KIT/HT-ALZ pipelines place Hoth in oncology/biotech with a focused cancer therapy strategy.
|
$15.91M |
$1.21
+3.42%
|
|
MRKR
Marker Therapeutics, Inc.
Marker Therapeutics develops MAR-T cell therapies, a cell-based immunotherapy platform targeting cancer.
|
$15.79M |
$1.24
+12.73%
|
|
CRIS
Curis, Inc.
Curis's core business is oncology-focused biotech developing cancer therapies, anchored by emavusertib.
|
$15.62M |
$1.25
+11.06%
|
|
ELTP
Elite Pharmaceuticals, Inc.
Elite focuses on the development, manufacture, and sale of generic drugs across a broad pipeline.
|
$15.47M |
$0.52
|
Showing page 21 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
